Atlas Arteria (ASX:ALX) YoY EBITDA Growth: -19.64% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ALX Atlas Arteria Ltd ASX:ALX
77 GF Score
Price A$4.82
GF Value A$5.88
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Atlas Arteria YoY EBITDA Growth?

Atlas Arteria ASX:ALX -0.41% 77 YoY EBITDA Growth is -19.64% as of Dec. 2025. GuruFocus rates ASX:ALX with a GF Score™ of 77/100 and a GF Value™ of A$5.88 (Modestly Undervalued). The stock has 5 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Atlas Arteria's YoY EBITDA Growth for the quarter that ended in Dec. 2025 was -19.64%.

Atlas Arteria's EBITDA per Share for the six months ended in Dec. 2025 was A$0.14.

Atlas Arteria YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Atlas Arteria's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atlas Arteria YoY EBITDA Growth Chart

Atlas Arteria Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 240.22 18.21 -20.81 4.44 -18.95

Atlas Arteria Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.86 -8.00 17.48 -18.84 -19.64
ASX:ALX
77GF Score
Atlas Arteria Ltd ASX:ALX
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atlas Arteria YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Atlas Arteria's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(0.248-0.306)/ | 0.306 |
=-18.95 %

Atlas Arteria's YoY EBITDA Growth for the quarter that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (Q: Dec. 2025 )
=(EBITDA per Share (Q: Dec. 2025 )-EBITDA per Share (Q: Dec. 2024 )) / | EBITDA per Share (Q: Dec. 2024 )) |
=(0.135-0.168)/ | 0.168 |
=-19.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -19.64% mean?
Atlas Arteria (ASX:ALX) has a YoY EBITDA Growth of -19.64% as of Dec. 2025. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Atlas Arteria and its competitors.
Is Atlas Arteria's YoY EBITDA Growth too high?
Atlas Arteria's current YoY EBITDA Growth is -19.64%. Overall, Atlas Arteria has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Atlas Arteria's YoY EBITDA Growth compare to competitors?
Atlas Arteria's YoY EBITDA Growth of -19.64% can be compared against companies in the Construction industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Construction company?
A good YoY EBITDA Growth depends on the Construction industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Atlas Arteria and its competitors. Atlas Arteria's current YoY EBITDA Growth is -19.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atlas Arteria stock overvalued right now?
Based on GuruFocus' analysis, Atlas Arteria (ASX:ALX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$5.88, compared to a current price of A$4.82 — trading 18% below its estimated fair value. The current YoY EBITDA Growth is -19.64%. Atlas Arteria's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Atlas Arteria (ASX:ALX), the current YoY EBITDA Growth is -19.64% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Atlas Arteria (ASX:ALX) Overvalued in 2026?

Based on GuruFocus' analysis, Atlas Arteria stock appears to be undervalued. The current stock price of A$4.82 is trading 18% below its estimated GF Value™ of A$5.88. GuruFocus considers Atlas Arteria to be Modestly Undervalued.

Key valuation signals for ASX:ALX:

  • YoY EBITDA Growth: -19.64%
  • GF Value™: A$5.88 vs. price of A$4.82 (18% below fair value)
  • GF Score™: 77/100 with 5 warning signs

No single metric tells the full story. See the ASX:ALX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Atlas Arteria Business Description

Other Exchanges MAQAF:USAM82:Germany
Address 180 Flinders Street, Level 1, Melbourne, VIC, AUS, 3000
Atlas Arteria is a global toll-road investor created out of the reorganization of Macquarie Infrastructure Group in 2010. The firm's main asset is a 30.82% stake in APRR. APRR owns concessions to toll more than 2,300 kilometers of motorways in eastern France, most ending by late 2035. The firm also wholly owns the Dulles Greenway and 66.67% of the Chicago Skyway, both in the US.
77GF Score

Get the complete analysis for ASX:ALX

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$4.82
Price
A$5.88
GF Value